Vitrolife AB AI Stock Analysis
Want to see SE:VITR full AI Analyst Report?
Vitrolife AB (VITR) AI Stock Analysis
Vitrolife AB
(Nasdaq OMX AB:VITR)
The overall score of 58 reflects a company in transition with significant strengths offset by a major financial overhang. The most impactful positive factors are the strong operational momentum and bullish technical trends, driven by robust technology sales and a promising product pipeline, as highlighted in a positive earnings call. The company's ability to generate solid free cash flow provides a crucial buffer. However, the score is heavily constrained by the massive non-cash impairment charges that have devastated reported net income and eroded shareholder equity, resulting in a deeply negative P/E ratio and a precarious financial profile.
Vitrolife AB (VITR) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 12.32B
- Dividend Yield
- 0.93%
- Average Volume (3M)
- 205.32K
- Price to Earnings (P/E)
- -3.2
- Beta (1Y)
- 0.48
- Revenue Growth
- -1.94%
- EPS Growth
- -1223.74%
- Country
- Sweden
- Employees
- 1,088
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Vitrolife AB Business Overview & Revenue Model
Company Description
Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, such...
How the Company Makes Money
Vitrolife makes money primarily by selling products and solutions to fertility clinics, IVF laboratories, and other reproductive health customers, with revenue generally derived from recurring consumables and from higher-value equipment and software...
Vitrolife AB Earnings Call Summary
The call was clearly positive overall. The company reported 6% group organic growth, higher EBITDA and margins, strong technology momentum, progress on restructuring, improving regional IVF and reimbursement trends, and a record innovation pipeline. These positives outweighed the challenges, which included weak Chinese IVF cycles, APAC consumables declines, Middle Eastern softness, higher material and inflationary costs, lower year-over-year operating cash flow and a slight increase in leverage.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said 21% growth in technologies was “very high” and that maintaining “these type of growth levels” would be “tough,” although the funnel looks good; China’s cycles are “likely to stay that way in 2027,” while most other APAC markets are growing, albeit with “lower growth than we see in Americas or lower growth than we see in Western Europe.” The Americas Latin America headwind is expected to continue until “probably end of Q1,” with declines “slowing” and the trend “flattening out,” while Western Europe consumables growth was “high single digits.” The restructuring program remains “on plan and on time,” targeting annual savings of SEK 65 million, with an 8% gross headcount reduction, a 2.5% headcount addition in sales and marketing, IT and other roles, and a 5.5% net headcount reduction; management said there were “no major changes in headcount additions, but still some more to do.” 2027 is “set to be our best ever year” for the number and size of product launches, although revenue takes “a little bit of time” to filter through, and the time from Gate 4 to launch has been “halved from previous quarters.”
Vitrolife AB Financial Statement Overview
Summary
Financial performance is deeply bifurcated. The income statement is alarming, showing massive net losses (SEK -4.96B TTM) due to significant impairment charges, which have severely eroded shareholder equity. However, the balance sheet remains conservatively financed with low debt, and cash flow generation is a critical strength, with TTM free cash flow of SEK 603M confirming the losses are primarily non-cash. The score reflects this high-risk, high-cash-generation paradox.
Income Statement
18Very NegativeBalance Sheet
55NeutralCash Flow
65Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.44B | 3.44B | 3.61B | 3.51B | 3.23B | 1.68B |
| Gross Profit | 1.98B | 2.00B | 2.13B | 1.98B | 1.79B | 1.05B |
| EBITDA | -4.35B | -4.39B | 1.23B | -3.19B | 977.00M | 579.60M |
| Net Income | -4.96B | -5.01B | 513.00M | -3.85B | 394.00M | 341.00M |
Balance Sheet | ||||||
| Total Assets | 11.42B | 11.12B | 17.45B | 16.33B | 20.55B | 19.43B |
| Cash, Cash Equivalents and Short-Term Investments | 860.00M | 809.00M | 1.14B | 861.00M | 578.00M | 630.09M |
| Total Debt | 1.73B | 1.60B | 2.09B | 2.09B | 2.23B | 2.48B |
| Total Liabilities | 3.30B | 3.23B | 3.81B | 3.61B | 3.81B | 4.09B |
| Stockholders Equity | 8.12B | 7.89B | 13.64B | 12.72B | 16.74B | 15.32B |
Cash Flow | ||||||
| Free Cash Flow | 603.00M | 460.00M | 815.00M | 638.00M | 549.00M | 321.86M |
| Operating Cash Flow | 696.00M | 635.00M | 907.00M | 757.00M | 636.00M | 384.31M |
| Investing Cash Flow | -215.00M | -302.00M | -377.00M | -124.00M | -144.00M | -6.52B |
| Financing Cash Flow | -751.00M | -553.00M | -286.00M | -300.00M | -582.00M | 5.75B |
Vitrolife AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VITR, the sentiment is Positive. The current price of 117.70 is above the 20-day moving average (MA) of 114.54, above the 50-day MA of 102.05, and above the 200-day MA of 96.26, indicating a bullish trend. The MACD of 5.11 indicates Positive momentum. The RSI at 68.90 is Neutral, neither overbought nor oversold. The STOCH value of 48.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:VITR.
Vitrolife AB Peers Comparison
Overall Rating
SE:CEVI83Outperform
SE:GETI.B67Neutral
SE:XVIVO64Neutral
SE:VITR58Neutral
SE:BACTI.B53Neutral
SE:BICO40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | SEK 4.83B | 35.03 | 15.23% | 1.36% | 1.95% | -8.91% | |
| 67Neutral | SEK 75.53B | 26.69 | 9.13% | 1.71% | -3.90% | 37.73% | |
| 64Neutral | SEK 6.17B | 47.92 | 5.89% | ― | 17.83% | 330.94% | |
| 58Neutral | SEK 15.94B | -3.21 | -61.57% | 0.93% | -1.94% | -1223.74% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 53Neutral | SEK 544.93M | 86.39 | 1.93% | ― | -0.51% | ― | |
| 40Underperform | SEK 1.10B | -4.82 | -28.59% | ― | -5.27% | 34.38% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:VITR | Vitrolife AB | 117.70 | -22.85 | -16.26% | |
| SE:GETI.B | Getinge AB (UK) | 277.30 | 74.58 | 36.79% | |
| SE:BICO | BICO Group AB Class B | 15.58 | -3.02 | -16.24% | |
| SE:CEVI | CellaVision AB | 202.50 | 50.09 | 32.87% | |
| SE:XVIVO | Xvivo Perfusion AB | 196.00 | 31.00 | 18.79% | |
| SE:BACTI.B | Bactiguard Holding AB | 15.55 | -3.20 | -17.07% |
Vitrolife AB Corporate Events
Vitrolife Appoints Nomination Committee for 2027 AGM
Vitrolife has appointed the Nomination Committee responsible for preparing proposals ahead of its 2027 Annual General Meeting, comprising representatives appointed by major shareholders and the Board Chair. The committee’s formation establishes the c...
Vitrolife names Elin Frostehav as next CEO, sets interim leadership
Vitrolife Group has announced a leadership transition, appointing Elin Frostehav as its next President and Chief Executive Officer, with her taking up the role no later than May 1, 2027.Senior Vice President Innovation Rickard Ericsson will serve as...
Vitrolife lifts margins and launches major buyback as technologies drive growth
Vitrolife AB reported third-quarter sales of SEK 884 million, representing 6% organic growth in local currencies excluding exited product lines and 4% total growth in local currencies. Regional performance was strongest in EMEA and the Technologies p...
Vitrolife schedules Q3 2026 report release and investor webcast
Vitrolife AB will publish its interim report for the third quarter of 2026 on 22 October, with the release scheduled for 08:00 am CET. The company will follow the publication with a conference call and webcast for investors, analysts and financial me...
Vitrolife expands Americas leadership as Erin Schardt joins executive team
Vitrolife Group has expanded the role of Erin Schardt, appointing her Senior Vice President and General Manager, Americas, with responsibility for both North and South America, and adding her to the Executive Management Team. The move recognizes her...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026
